{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:15:09Z","timestamp":1794244509018,"version":"4.9.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We aimed to evaluate the efficacy and safety of adding apatinib, to sintilimab and chemotherapy in the neoadjuvant treatment of early triple-negative breast cancer (TNBC). In the phase 2 NeoSAC trial, patients with early TNBC received six cycles of apatinib, sintilimab, nab-paclitaxel, and carboplatin followed by surgery. The primary endpoint was pathological complete response (pCR) rate. Specimens collected pre-neoadjuvant therapy and post-surgery were retained for comprehensive analysis of predictive biomarkers and the impact on the tumor microenvironment. Among 34 enrolled patients, 24 achieved pCR (70.6%; 95% confidence interval (CI), 53.0-85.3), and 79.4% (95% CI, 65.1-93.7) had residual cancer burden 0-I. Imaging evaluation showed 21 complete responses (61.8%) and 13 partial responses (38.2%). The most common grade 3-4 adverse events were leukopenia (47%), neutropenia (36%), and thrombocytopenia (24%). The 36-month disease-free survival rate stood at 94.1% with a median follow-up of 39.1 months. Notably, baseline high ImmuneScore, immune cell infiltration, and enrichment of interferon-related pathways correlated with pCR. Comparison of pre-neoadjuvant and post-surgery data revealed that the pCR group treated with this novel regimen exhibited an upregulation of distinct immune cell subsets, thereby activating the tumor microenvironment. Moreover, higher oxeiptosis scores were associated with an increased likelihood of achieving pCR. Following neoadjuvant therapy, the pCR group showed a decrease in oxeiptosis score, whereas the non-pCR group exhibited an increase. Our study suggests that apatinib, sintilimab combined with carboplatin and nab-paclitaxel chemotherapy showed a promising clinical activity and manageable safety profile in early TNBC and merits further study. ClinicalTrials.gov registration: NCT04722718.<\/jats:p>","DOI":"10.1038\/s41392-025-02137-7","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T18:01:52Z","timestamp":1738864912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial"],"prefix":"10.1038","volume":"10","author":[{"given":"Guoshuang","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaozhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengfeng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuxing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2887-7985","authenticated-orcid":false,"given":"Hongnan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9432-1902","authenticated-orcid":false,"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1266-8943","authenticated-orcid":false,"given":"Jiuda","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"2137_CR1","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre, R. A. & Goetz, M. P. Advances in systemic therapies for triple negative breast cancer. BMJ 381, e071674 (2023).","journal-title":"BMJ"},{"key":"2137_CR2","doi-asserted-by":"publisher","first-page":"12478","DOI":"10.3390\/ijms241512478","volume":"24","author":"PV Bhardwaj","year":"2023","unstructured":"Bhardwaj, P. V., Wang, Y., Brunk, E., Spanheimer, P. M. & Abdou, Y. G. Advances in the management of early-stage triple-negative breast cancer. Int J. Mol. Sci. 24, 12478 (2023).","journal-title":"Int J. Mol. Sci."},{"key":"2137_CR3","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring, L. M. et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin. Cancer Res 26, 2838\u20132848 (2020).","journal-title":"Clin. Cancer Res"},{"key":"2137_CR4","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid, P. et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N. Engl. J. Med. 386, 556\u2013567 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2137_CR5","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, 810\u2013821 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2137_CR6","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf, E. A. et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 396, 1090\u20131100 (2020).","journal-title":"Lancet"},{"key":"2137_CR7","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","volume":"33","author":"L Gianni","year":"2022","unstructured":"Gianni, L. et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann. Oncol. 33, 534\u2013543 (2022).","journal-title":"Ann. Oncol."},{"key":"2137_CR8","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","volume":"15","author":"KA Khan","year":"2018","unstructured":"Khan, K. A. & Kerbel, R. S. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat. Rev. Clin. Oncol. 15, 310\u2013324 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2137_CR9","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","volume":"25","author":"OE Rahma","year":"2019","unstructured":"Rahma, O. E. & Hodi, F. S. The Intersection between tumor angiogenesis and immune suppression. Clin. Cancer Res. 25, 5449\u20135457 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2137_CR10","doi-asserted-by":"publisher","first-page":"e000696","DOI":"10.1136\/jitc-2020-000696","volume":"8","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. J. Immunother. Cancer 8, e000696 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2137_CR11","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1158\/1078-0432.CCR-21-4313","volume":"28","author":"L Chen","year":"2022","unstructured":"Chen, L. et al. Famitinib with camrelizumab and Nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-Plus): an open-label, single-arm, phase II trial. Clin. Cancer Res. 28, 2807\u20132817 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2137_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","volume":"23","author":"C Yau","year":"2022","unstructured":"Yau, C. et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 23, 149\u2013160 (2022).","journal-title":"Lancet Oncol."},{"key":"2137_CR13","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.21.02091","volume":"40","author":"Q Xu","year":"2022","unstructured":"Xu, Q. et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase II trial. J. Clin. Oncol. 40, 1795\u20131805 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2137_CR14","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","volume":"29","author":"F Poggio","year":"2018","unstructured":"Poggio, F. et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann. Oncol. 29, 1497\u20131508 (2018).","journal-title":"Ann. Oncol."},{"key":"2137_CR15","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1007\/s10238-022-00940-y","volume":"23","author":"F Zhao","year":"2023","unstructured":"Zhao, F. et al. Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis. Clin. Exp. Med. 23, 2025\u20132040 (2023).","journal-title":"Clin. Exp. Med."},{"key":"2137_CR16","doi-asserted-by":"publisher","first-page":"S408","DOI":"10.1016\/j.annonc.2021.08.400","volume":"32","author":"S Loibl","year":"2021","unstructured":"Loibl, S. et al. 119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after \u22654 years of follow-up: BrighTNess, a randomized phase III trial. Ann. Oncol. 32, S408 (2021).","journal-title":"Ann. Oncol."},{"key":"2137_CR17","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","volume":"25","author":"L Voorwerk","year":"2019","unstructured":"Voorwerk, L. et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat. Med. 25, 920\u2013928 (2019).","journal-title":"Nat. Med."},{"key":"2137_CR18","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1200\/JCO.18.01842","volume":"37","author":"M Untch","year":"2019","unstructured":"Untch, M. et al. NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69-GeparSepto. J. Clin. Oncol. 37, 2226\u20132234 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2137_CR19","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/ijc.33830","volume":"150","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial. Int J. Cancer 150, 654\u2013662 (2022).","journal-title":"Int J. Cancer"},{"key":"2137_CR20","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","volume":"30","author":"S Loibl","year":"2019","unstructured":"Loibl, S. et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann. Oncol. 30, 1279\u20131288 (2019).","journal-title":"Ann. Oncol."},{"key":"2137_CR21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1200\/JCO.2023.41.16_suppl.507","volume":"41","author":"SR Stecklein","year":"2023","unstructured":"Stecklein, S. R. et al. Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial. JCO 41, 507\u2013507 (2023).","journal-title":"JCO"},{"key":"2137_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00500-3","volume":"8","author":"FO Ademuyiwa","year":"2022","unstructured":"Ademuyiwa, F. O. et al. A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. NPJ Breast Cancer 8, 134 (2022).","journal-title":"NPJ Breast Cancer"},{"key":"2137_CR23","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1200\/JCO.2023.41.16_suppl.602","volume":"41","author":"Z Jiang","year":"2023","unstructured":"Jiang, Z. et al. Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin followed by adjuvant tislelizumab in patients with early triple-negative breast cancer. JCO 41, 602\u2013602 (2023).","journal-title":"JCO"},{"key":"2137_CR24","doi-asserted-by":"crossref","unstructured":"Zhang, L. et al. Abstract PO1-28-08: The Efficacy and Safety Results of Neoadjuvant Phase II study of Anlotinib plus Sintilimab Combined with Chemotherapy in Triple-negative Breast Cancer (NeoSACT). Cancer Res. 84, PO1-28\u201308 (2024).","DOI":"10.1158\/1538-7445.SABCS23-PO1-28-08"},{"key":"2137_CR25","doi-asserted-by":"publisher","first-page":"117822341879225","DOI":"10.1177\/1178223418792250","volume":"12","author":"Y Alnimer","year":"2018","unstructured":"Alnimer, Y., Hindi, Z. & Katato, K. The effect of perioperative bevacizumab on disease-free and overall survival in locally advanced HER-2 negative breast cancer: a meta-analysis. Breast Cancer (Auckl.) 12, 1178223418792250 (2018).","journal-title":"Breast Cancer (Auckl.)"},{"key":"2137_CR26","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu, J. et al. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial. JAMA 330, 2064\u20132074 (2023).","journal-title":"JAMA"},{"key":"2137_CR27","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1158\/1078-0432.CCR-20-3113","volume":"27","author":"BV Sinn","year":"2021","unstructured":"Sinn, B. V. et al. Immune-related gene expression predicts response to neoadjuvant chemotherapy but not additional benefit from PD-L1 inhibition in women with early triple-negative breast cancer. Clin. Cancer Res. 27, 2584\u20132591 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2137_CR28","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2020.05.015","volume":"31","author":"T Karn","year":"2020","unstructured":"Karn, T. et al. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann. Oncol. 31, 1216\u20131222 (2020).","journal-title":"Ann. Oncol."},{"key":"2137_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1139\/bcb-2021-0399","volume":"100","author":"J Zhang","year":"2022","unstructured":"Zhang, J., Gao, R.-F., Li, J., Yu, K. & Bi, K.-X. Alloimperatorin activates apoptosis, ferroptosis, and oxeiptosis to inhibit the growth and invasion of breast cancer cells in vitro. Biochem Cell Biol. 100, 213\u2013222 (2022).","journal-title":"Biochem Cell Biol."},{"key":"2137_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06939-5","volume":"15","author":"X An","year":"2024","unstructured":"An, X. et al. Oxidative cell death in cancer: mechanisms and therapeutic opportunities. Cell Death Dis. 15, 556 (2024).","journal-title":"Cell Death Dis."},{"key":"2137_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259\u2013271 (2015).","journal-title":"Ann. Oncol."},{"key":"2137_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).","journal-title":"Nat. Commun."},{"key":"2137_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000688","volume":"5","author":"D Eiger","year":"2020","unstructured":"Eiger, D., Brand\u00e3o, M. & de Azambuja, E. Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer. ESMO Open 5, e000688 (2020).","journal-title":"ESMO Open"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02137-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02137-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02137-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T18:01:54Z","timestamp":1738864914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02137-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2137"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02137-7","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}